Key Highlights

  • In data for the November 18, 2026 session, Stem (NYSE:STEM) and Prenetics slid approximately 37% to 38%, each after posting third-quarter numbers.
  • Stem now projects 2026 Revenue of USD 132 million to USD 142 million, down from USD 140 million to USD 190 million, and its year-end ARR target has been pared to USD 50 million to USD 55 million.
  • Prenetics came in slightly ahead on revenue at USD 64.1 million, but it foresees a larger second-half adjusted EBITDA Deficit of USD 30 million to USD 35 million, versus USD 8 million to USD 12 million before.
  • Stem published its results on November 16, meaning some of the decline may predate November 18, and the reported move could span several sessions.

Stem Contracts Around Its Core

Stem (NYSE:STEM) offers software and services for solar and battery storage assets. Revenue for the third quarter was USD 36.7 million, a 4% fall from last year and under the roughly USD 40.3 million analysts had penciled in. Bookings fell, landing at USD 27.6 million after USD 36.8 million the quarter before. Profit metrics improved, though: adjusted EBITDA hit USD 7.1 million compared with USD 2.0 million a year ago, and the non-GAAP gross Margin widened 11 points to 58%. Annual Recurring Revenue advanced 6% to USD 64.0 million, powered by PowerTrack, whose ARR rose 14% to USD 44.4 million. Managed services and battery hardware resale are being phased out, and the Athena software IP is going to Voltus in a USD 10 million cash sale. Fiscal 2026 revenue guidance now sits at USD 132 million to USD 142 million, the year-end ARR goal is lower at USD 50 million to USD 55 million, and the earlier USD 65 million to USD 70 million has been dropped, while adjusted EBITDA guidance moved up to USD 15 million to USD 20 million. Cash closed at USD 36.9 million. After the release the stock slid 12.05% in the session, closing at USD 1.97, and fell 20.81% more after hours, beneath its 52-week low.

Prenetics Accepts Heavier Spending

Prenetics has narrowed its focus to the IM8 supplement brand. Its third-quarter revenue of USD 64.1 million rose 38% from the previous quarter and stood at roughly 3.3 times the year-earlier figure, edging past its USD 63 million to USD 64 million guidance. IM8 generated USD 62.9 million, with a 64% gross margin. Net loss totalled USD 25.4 million, inclusive of a non-cash USD 7.2 million Warrant valuation charge, and adjusted EBITDA was minus USD 12.7 million once roughly USD 39.3 million of Acquisition Marketing was counted, up from USD 35.7 million in the second quarter. Fiscal 2026 IM8 revenue guidance of USD 215 million to USD 222 million was reaffirmed, with at least USD 400 million targeted for 2027. Still, the expected second-half adjusted EBITDA deficit deepened to USD 30 million to USD 35 million, compared with USD 8 million to USD 12 million earlier, while marketing ramps. Shares moved to around USD 9.39 from USD 16.33, while cash and current financial Assets sat at USD 111.5 million on September 30.

Two Dissimilar Recalibrations

Both drops reflect the same underlying worry: updates that pushed profitability or scale into the future were unwelcome. Stem is contracting its revenue to focus on software with better margins, which lifts margin quality but shrinks the company. It has also received an exchange letter on Market Value and Shareholder Equity and begun a strategic review, adding uncertainty about its eventual form. Prenetics is putting growth ahead of near-term earnings, gambling that heavy customer acquisition will create a sizeable subscription base. Investor reaction suggests skepticism about how quickly that outlay will be recovered. For Stem, the next checkpoints are the strategic review and PowerTrack's trajectory. For Prenetics, attention will centre on fourth-quarter IM8 revenue, guided at USD 73 million to USD 80 million, and on the cost of acquiring customers.

Where Things Stand

Stem (NYSE:STEM) dropped after reducing revenue and ARR guidance as it leaves lower-margin lines, while Prenetics fell after signalling a deeper loss to fund expansion. Each must now demonstrate that its approach can Yield profitable scale.